Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Trinity College of Arts and Sciences, Duke University, Durham, NC 27708, USA.
Curr Oncol. 2023 Aug 27;30(9):7891-7903. doi: 10.3390/curroncol30090573.
Multiple myeloma (MM) is a common hematological malignancy that has fostered several new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field has advanced over the past 2 decades, the majority of patients will develop resistance to these treatments, causing the need for new therapeutic targets. SLAMF7 is an attractive therapeutic target in multiple myeloma, and a monoclonal antibody that targets SLAMF7 has shown consistent beneficial outcomes in clinical trials to date. In this review, we will focus on the structure and regulation of SLAMF7 and its mechanism of action. The most recent clinical trials will be reviewed to further understand the clinical implications and improve the prognosis of MM. Furthermore, the efficacy of anti-SLAMF7 monoclonal antibodies combined with standard therapies and possible resistance mechanisms will be discussed. This review aimed to provide a detailed summary of the role of SLAMF7 in the pathogenesis of patients with MM and the rationale for further investigation into SLAMF7-mediated molecular pathways associated with MM development.
多发性骨髓瘤（MM）是一种常见的血液系统恶性肿瘤，已经产生了几种新的治疗方法来治疗新诊断或复发的 MM。尽管在过去的 20 年里，该领域取得了进展，但大多数患者会对这些治疗产生耐药性，因此需要新的治疗靶点。SLAMF7 是多发性骨髓瘤中一个有吸引力的治疗靶点，一种针对 SLAMF7 的单克隆抗体在迄今为止的临床试验中显示出一致的有益结果。在这篇综述中，我们将重点介绍 SLAMF7 的结构和调节及其作用机制。将回顾最近的临床试验，以进一步了解其临床意义并改善 MM 的预后。此外，还将讨论抗 SLAMF7 单克隆抗体与标准疗法联合应用的疗效以及可能的耐药机制。本综述旨在详细总结 SLAMF7 在 MM 患者发病机制中的作用，以及进一步研究与 MM 发展相关的 SLAMF7 介导的分子途径的合理性。
Zotero 插件